Hims & Hers Health Stock Jumps Nearly 28% on Plans to Offer GLP-1 Weight-Loss Drugs

The company said the shots will be distributed through its pharmacy partners, with plans to expand the program's offerings once "consistent supply" is available. Guidance Doesn't Include Weight-Loss Drug's Impact Key Takeaways Shares of Hims & Hers Health (HIMS) surged close to 28% Monday after the telehealth company said it would begin offering GLP-1 injections as part of its weight-loss package of drugs. The market for weight-loss treatments has exploded in recent years, led by drugs containing the same a ...